BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, Andrikou K, Muffatti F, Balzano G, Reni M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533-1539. [PMID: 27423449 DOI: 10.1016/j.ejso.2016.06.398] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Ricke J, Westphalen CB, Seidensticker M. Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. Visc Med 2020;36:359-63. [PMID: 33178732 DOI: 10.1159/000509897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yu X, Gu J, Fu D, Jin C. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. International Journal of Surgery 2017;48:149-54. [DOI: 10.1016/j.ijsu.2017.10.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
4 Klar E, Büchler MW, Lang H, Lordick F, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN. Oligometastases of Gastrointestinal Cancer Origin. Visc Med 2017;33:76-81. [PMID: 28612021 DOI: 10.1159/000463468] [Reference Citation Analysis]
5 Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol 2020;2020:8679751. [PMID: 33102398 DOI: 10.1155/2020/8679751] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, De Vita F, Falconi M, Frassineti GL, Giommoni E, Macchini M, Malleo G, Silvestris N, Tudisco A, Vasile E, Reni M. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Crit Rev Oncol Hematol 2021;169:103571. [PMID: 34923121 DOI: 10.1016/j.critrevonc.2021.103571] [Reference Citation Analysis]
7 Bailey RE, Surapaneni PK, Core J, Vidal LLC, LeGout J, Ritchie C, Frey G, McKinney JM, Sella D, Paz-Fumagalli R, Toskich B, Mody K. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. J Gastrointest Oncol. 2019;10:688-694. [PMID: 31392049 DOI: 10.21037/jgo.2019.03.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
8 Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schöb O, Giryes A, Decker M, Abdel-Rahman O. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol 2017; 23(10): 1872-1880 [PMID: 28348494 DOI: 10.3748/wjg.v23.i10.1872] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
9 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Gu J, Xu Z, Ma Y, Chen H, Wang D, Deng X, Cheng D, Xie J, Jin J, Zhan X, Shi Y, Shi Y, Zhu Y, Shen B, Peng C. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. J Gastrointest Oncol 2020;11:319-28. [PMID: 32399273 DOI: 10.21037/jgo.2020.03.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol 2021;45:101607. [PMID: 33662776 DOI: 10.1016/j.clinre.2020.101607] [Reference Citation Analysis]
12 Hackert T, Klaiber U, Büchler MW. Response: the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient?" The Case of Unresectable Pancreatic Cancer After Neoadjuvant Treatment. Ann Surg 2020;271:e108. [PMID: 31651537 DOI: 10.1097/SLA.0000000000003652] [Reference Citation Analysis]
13 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
14 Shao Y, Feng J, Hu Z, Wu J, Zhang M, Shen Y, Zheng S. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study. Ann Med Surg (Lond) 2021;62:490-4. [PMID: 33680449 DOI: 10.1016/j.amsu.2020.11.037] [Reference Citation Analysis]
15 Niesen W, Primavesi F, Gasteiger S, Neoptolemos J, Hackert T, Stättner S. Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. Eur Surg 2019;51:153-64. [DOI: 10.1007/s10353-019-0589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Nie D, Lai G, An G, Wu Z, Lei S, Li J, Cao J. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Front Oncol 2021;11:719253. [PMID: 34604055 DOI: 10.3389/fonc.2021.719253] [Reference Citation Analysis]
17 Heinrich S, Watzka F, Lang H. Integrative Concepts for Liver Surgery. Visc Med 2020;36:351-8. [PMID: 33178731 DOI: 10.1159/000511043] [Reference Citation Analysis]
18 Voss N, Izbicki JR, Nentwich MF. Oligometastases in pancreatic cancer (Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis). Ann Gastroenterol Surg 2019;3:373-7. [PMID: 31346576 DOI: 10.1002/ags3.12255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Feng F, Cai W, Wang G, Chen W, Yang H, Sun M, Zhou L. Metastatic pancreatic adenocarcinomas could be classified into M1a and M1b category by the number of metastatic organs. BMC Gastroenterol 2020;20:289. [PMID: 32854631 DOI: 10.1186/s12876-020-01431-8] [Reference Citation Analysis]
21 Klaiber U, Hackert T. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Front Oncol. 2019;9:1501. [PMID: 31993372 DOI: 10.3389/fonc.2019.01501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Buanes TA. Role of surgery in pancreatic cancer. World J Gastroenterol 2017; 23(21): 3765-3770 [PMID: 28638216 DOI: 10.3748/wjg.v23.i21.3765] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
23 Heinrich S. Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection? Hepatobiliary Surg Nutr 2018;7:289-91. [PMID: 30221156 DOI: 10.21037/hbsn.2018.03.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 2021;28:1-25. [PMID: 33200538 DOI: 10.1002/jhbp.868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Dhayat SA, Mirgorod P, Lenschow C, Senninger N, Anthoni C, Vowinkel T. Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines. PLoS One 2017;12:e0173374. [PMID: 28267771 DOI: 10.1371/journal.pone.0173374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Reference Citation Analysis]
28 Lu Y, Zhou Y, Cao Y, Shi Z, Meng Q. A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma. Med Sci Monit 2019;25:3683-91. [PMID: 31102397 DOI: 10.12659/MSM.913533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Balzano G, Pecorelli N, Falconi M, Reni M. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient? Ann Surg 2020;271:e106-7. [PMID: 31804386 DOI: 10.1097/SLA.0000000000003655] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Arvaniti M, Danias N, Igoumenidis M, Smyrniotis V, Tsounis A, Sarafis P. Comparison of Quality of Life before and after pancreaticoduodenectomy: a prospective study. Electron Physician 2018;10:7054-62. [PMID: 30128096 DOI: 10.19082/7054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Jin T, Dai C, Xu F. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects. Ther Adv Med Oncol 2020;12:1758835920933034. [PMID: 32636941 DOI: 10.1177/1758835920933034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg 2021. [PMID: 34628591 DOI: 10.1007/s13304-021-01186-1] [Reference Citation Analysis]
33 Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget 2017;8:15004-13. [PMID: 28122342 DOI: 10.18632/oncotarget.14745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 2020;72:39-45. [PMID: 31997233 DOI: 10.1007/s13304-020-00710-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
35 Mitsuka Y, Yamazaki S, Yoshida N, Yan M, Higaki T, Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol 2020;18:294. [PMID: 33172482 DOI: 10.1186/s12957-020-02058-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lopez-lopez V, Robles-campos R, López-conesa A, Brusadin R, Carbonel G, Gomez-ruiz A, Ruiz JJ, Parrilla P. Surgical resection of liver metastasis in pancreatic and periampullary carcinoma. Minerva Chir 2019;74. [DOI: 10.23736/s0026-4733.18.07972-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Silvestris N, Brunetti O, Bittoni A, Cataldo I, Corsi D, Crippa S, D'Onofrio M, Fiore M, Giommoni E, Milella M, Pezzilli R, Vasile E, Reni M. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2020;12:E1681. [PMID: 32599886 DOI: 10.3390/cancers12061681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, Gobbo S, Martini PT, Capelli P, D'Onofrio M, Malleo G, Maggino L, Viviani E, Butturini G. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Ann Surg Oncol 2017;24:2397-403. [PMID: 28516291 DOI: 10.1245/s10434-017-5885-4] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
39 Ouyang H, Ma W, Zhang T, Liu F, Zhao L, Fang M, Quan M, Pan Z. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. Pancreatology 2018;18:983-9. [PMID: 30287168 DOI: 10.1016/j.pan.2018.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Yang J, Zhang J, Lui W, Huo Y, Fu X, Yang M, Hua R, Wang L, Sun Y. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford) 2020;22:91-101. [PMID: 31262486 DOI: 10.1016/j.hpb.2019.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
41 Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M;  Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675. [PMID: 31288786 DOI: 10.1186/s12885-019-5889-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
42 Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control 2020;27:1073274820976593. [PMID: 33238715 DOI: 10.1177/1073274820976593] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Gül-Klein S, Schmuck R, Modest DP, Pratschke J. [Treatment of colorectal and non-colorectal liver metastases: rationale for neoadjuvant therapeutic concepts]. Chirurg 2020;91:396-404. [PMID: 32291472 DOI: 10.1007/s00104-020-01133-7] [Reference Citation Analysis]
44 Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019;9:e033452. [PMID: 31818843 DOI: 10.1136/bmjopen-2019-033452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Noda Y, Tochigi T, Baliyan V, Kordbacheh H, Kambadakone A. Hepatobiliary contrast uptake patterns on gadoxetic acid-enhanced MRI in liver metastases from pancreatic ductal adenocarcinoma: can it predict prognosis? Eur Radiol 2021;31:276-82. [PMID: 32783131 DOI: 10.1007/s00330-020-07115-x] [Reference Citation Analysis]
46 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, Meijerink MR, Scheffer HJ. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel) 2021;13:1608. [PMID: 33807220 DOI: 10.3390/cancers13071608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Heinrich S, Lang H. Hepatic resection for primary and secondary liver malignancies. Innov Surg Sci 2017;2:1-8. [PMID: 31579727 DOI: 10.1515/iss-2017-0009] [Reference Citation Analysis]
48 Ozaki K, Hayashi H, Ikuta Y, Masuda T, Akaboshi S, Ogata K, Matumoto K, Ogawa K, Kamio T, Baba H, Takamori H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. Clin J Gastroenterol 2019;12:603-8. [PMID: 30993652 DOI: 10.1007/s12328-019-00965-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Fonseca GM, Braghiroli MIFM, Pirola Kruger JA, Coelho FF, Herman P. Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? Surg Oncol Clin N Am 2021;30:125-42. [PMID: 33220801 DOI: 10.1016/j.soc.2020.08.004] [Reference Citation Analysis]
50 Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, Büchler MW, Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 2019;45:1453-9. [PMID: 30981446 DOI: 10.1016/j.ejso.2019.03.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
51 Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Cancers (Basel). 2019;11. [PMID: 31374916 DOI: 10.3390/cancers11081095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
52 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]